Celerion Inc

1. Janssen Research & Development, LLC $39,067,119 301 payments
2. Bausch Health US, LLC $7,554,477 12 payments
3. Regeneron Pharmaceuticals, Inc. $7,242,116 14 payments
4. Neurocrine Biosciences, Inc. $6,257,304 99 payments
5. Takeda Pharmaceuticals U.S.A., Inc. $3,457,792 36 payments
6. Amgen Inc. $2,513,628 19 payments
7. Eli Lilly and Company $2,085,946 11 payments
8. PTC Therapeutics, Inc. $2,070,241 20 payments
9. Horizon Therapeutics plc $1,898,934 5 payments
10. Xeris Pharmaceuticals, Inc. $1,047,312 3 payments

1. Open-Label, Randomized, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Relative Bioavailability of Different Long-Acting Injectable Formulations of JNJ-68006861 and Multiple Doses of Oral JNJ-68006861 $7,281,825 38 payments
2. A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers $7,242,116 14 payments
3. A Phase 1 Randomized Double Blind Placebo Controlled Single and Multiple Ascending Dose Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics of JNJ 68179280 in Healthy Participants. $6,240,813 32 payments
4. A Randomized, Double-blnded, Multiple Dose, Placebo-Controlled, Parallel, Nested Crossover, Single Center Study $5,918,540 5 payments
5. A Phase 1, Single-dose, Open-label, Randomized, Parallel-group Study in Healthy Participants to Assess the Pharmacokinetic Bioequivalence of Intravenously Administered Nipocalimab (JNJ 80202135) Produced by Two Different Manufacturing Processes $4,558,460 12 payments
6. An Open label Randomized Parallel group Study to Assess the Bioequivalence of Ustekinumab Following a Single Subcutaneous Administration by Two Different Injection Devices in Healthy Participants $4,003,830 20 payments
7. A Single-Dose, Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Way Crossover Study to Evaluate the Effect of Loxo-292 on the QTC Interval in Healthy Adult Subjects $1,909,473 2 payments
8. An Open-label, Single-dose, Parallel Design Study to Assess the Relative Oral Bioavailability and Food Effect of Alternate JNJ-81241459 Formulations, and an Open-label, Fixed Sequence Design Study to Assess the Effects of Proton Pump Inhibitor Rabeprazol $1,885,597 7 payments
9. A Single-Dose, Open-label, Randomized, 2-Part Pivotal Study to Assess Bioequivalence of a New Apalutamide Film-Coated Tablet with Respect to Current Commercial Film-Coated Tablets and Food Effect of the New Tablet in Healthy Male Participants $1,884,821 10 payments
10. An Open label Randomized Parallel group Study to Assess the Pharmacokinetic Comparability of Subcutaneously Administered Guselkumab Delivered by 3 Different Devices in Healthy Participants $1,772,831 48 payments

1. Other $1,223,620 13 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.